admin – Page 4271 – Get News Story

Major Acquisition Introduces Game-Changing Energy and IoT Innovations, Setting the Stage for Long-Term Shareholder Value: Safe & Green Holdings Corp., (Stock Symbol: SGBX)

Development, Design and Fabrication of Modular Structures, Meeting the Demand for Safe and Green Solutions Across Various Industries.

Supports Third-Party and In-House Developers, Architects, Builders and Owners for Faster Execution, Greener Construction and Buildings of Higher Value.

Signed LOI for Transformative 100% Acquisition of Olenox and Machfu.com

Olenox’s Operations Include Three Vertically Integrated Business Units: Oil & Gas Production, Energy Services and Energy Technologies.

With Over 20,000 Gateways Deployed Globally, Machfu Delivers Real-Time Data Analytics, Predictive Maintenance and Operational Efficiency to Industrial Clients.

Michael McLaren, Recently Appointed CEO of SGBX as well as Founder and CEO of Olenox, to Assume Additional Role as Chairman of SGBX.

$1,274,752 Awarded by Favorable Legal Judgment, Delivering Substantial Value to Shareholders.

Safe & Green Holdings Corp., (Nasdaq: SGBX) a leading modular solutions company, operates under core capabilities which include the development, design, and fabrication of modular structures, meeting the demand for safe and green solutions across various intries. SGBX supports third-party and in-house developers, architects, builders, and owners in achieving faster execution, greener construction, and buildings of higher value.

LOI for Transformative Acquisition of Olenox and Machfu.com

On January 14th SGBX announced a binding Letter of Intent (“LOI”) to acquire 100% of the outstanding securities of New Asia Holdings Inc. (OTCQB: NAHD). The acquisition includes a diversified energy company Olenox Corp., a wholly owned subsidiary of NAHD. The SGBX acquisition also includes Machfu.com, a wholly owned subsidiary of Olenox, specializing in secure connectivity and automation solutions for industries such as oil & gas, utilities, and manufacturing.

Olenox’s operations include three vertically integrated business units: Oil & Gas Production, Energy Services, and Energy Technologies. Olenox specializes in acquiring and revitalizing underdeveloped energy assets, leveraging proprietary technologies and operational expertise to enhance production efficiency, lower costs, and minimize environmental impact.

Key achievements of Olenox include expanding production from 113 barrels of oil equivalent per day (BOE/day) to a projected 700 BOE/day through increased operational capacity and innovative technologies. By focusing on distressed and neglected oil and gas fields in Texas, Oklahoma, and Kansas, Olenox has created a scalable model that addresses industry inefficiencies while maintaining a strong commitment to sustainability. Following the acquisition of NAHD, SGBX will continue to maintain its current operations and fabrication of modular structures. In addition, the Company plans to leverage its existing facilities, including its Waldron facility in Durant, Oklahoma, to support its new operations in the oil and gas industry. SGBX management expects that this dual focus will enable the combined entity to achieve greater efficiencies and benefit from economies of scale across its business segments. This approach aligns with the Company’s overarching vision to lead advancements in sustainable energy, food, water, and shelter as essential pillars for fostering global resilience.

Olenox’s proprietary plasma pulse and ultrasonic cleaning tools set it apart from traditional energy players. These advanced technologies allow for cost-effective recovery of oil and gas while reducing the environmental footprint, ensuring alignment with global sustainability trends. Olenox’s Energy Services division, with its customized service rigs and reclamation capabilities, enhances the value of its production assets while generating additional revenue streams through third-party contracts.

Machfu.com is a trailblazer in the Industrial IoT sector. Its flagship product, the MachGateway®, and Edge-to-Enterprise™ software enable seamless integration of legacy systems with modern IoT platforms. With over 20,000 gateways deployed globally, Machfu has proven its ability to deliver real-time data analytics, predictive maintenance, and operational efficiency to industrial clients.

Machfu’s technology supports cost reduction and productivity gains by minimizing downtime and optimizing equipment performance. For example, its Bluetooth IoT gateways connect over 125 sensors per device, enabling scalable, low-cost solutions for monitoring and control in industrial environments. These capabilities directly address the growing demand for automation and digital transformation in energy and other key industries, creating high-margin recurring revenue opportunities for the combined entity.

In connection with the transaction, Michael McLaren, recently appointed CEO of SGBX, as well as founder and CEO of Olenox, will assume the additional role of Chairman of SGBX, succeeding Paul Galvin, who will remain on the board of directors.

SGBX CEO Michael McLaren stated, “We believe that the combination of Olenox and Machfu with Safe & Green will create a powerful, diversified entity with robust growth potential in both the energy and technology sectors. Olenox provides stable and growing revenues from its oil and gas assets, complemented by the scalability of Machfu’s recurring IoT revenue streams. We believe that this synergy will position the combined company to capture significant market opportunities in renewable energy, digital transformation, and industrial automation. By maintaining Safe & Green’s current modular operations, while leveraging facilities such as our Waldron facility to support oil and gas activities, we expect to achieve greater operational efficiencies and economies of scale. For Safe & Green shareholders, this transaction represents a strategic pivot toward high-growth markets. Olenox’s proven financial performance, including strong asset utilization and innovative technologies, enhances the Company’s equity position and profitability potential. Machfu’s advanced IoT capabilities further diversify the revenue base, providing exposure to a rapidly growing global market.”

Favorable Legal Judgment, Delivering Substantial Value to Shareholders

On December 27th SGBX announced a decisive legal victory in its litigation against EDI International, PC, and PVE, LLC. The Superior Court of Los Angeles County awarded a judgment in favor of Safe & Green Holdings, granting the Company $1,274,752 in damages, with additional potential awards for interest, legal costs, and attorney’s fees.

This judgment resolves claims related to intentional interference with prospective economic relations and contractual obligations, highlighting the Company’s steadfast commitment to protecting its interests and ensuring fairness for its shareholders.

The court ruled that the defendants’ actions disrupted critical economic relationships and contractual agreements, resulting in damages to Safe & Green Holdings. SGBX is committed to ensuring that the awarded damages benefit shareholders and contribute to its mission of advancing sustainable and innovative building solutions.

For more information on $SGBX, visit https://www.safeandgreenholdings.com/

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website

Media Contact
Company Name: Safe & Green Holdings Corp
Contact Person: CEO Michael McLaren, Chairman and CEO
Email: Send Email
Phone: 646-240-4235
Address:990 Biscayne Boulevard Suite 501, Office 12
City: Miami
State: Florida
Country: United States
Website: https://www.safeandgreenholdings.com/

SYNIDO Makes a Remarkable Debut at NAMM 2025

Anaheim, California – The 2025 NAMM Show, held from January 23 to January 25, witnessed an unprecedented scale of participation, with over 3,000 brands showcasing their latest innovations in musical instruments and audio technology. Among these, SYNIDO, a cutting-edge brand specializing in MIDI controllers and audio interfaces, made an impressive debut that captivated attendees with its groundbreaking designs, innovative features, and deep commitment to user experience.

Making Waves with Bold Innovation

As a newcomer to the global music technology scene, SYNIDO immediately stood out. With a booth (#10800) that drew large crowds, the brand unveiled its fresh take on industrial design, combining bold colors with a fashion-forward aesthetic that resonated strongly with international audiences. SYNIDO’s mission to empower creators with tools that match their creativity was evident throughout its display, which featured innovative products designed to inspire musicians, producers, and content creators alike.

画板 6

Product Highlights: Blending Style and Performance

A star of the SYNIDO booth was the TempoPAD C16, making its first public appearance ahead of its official launch in April 2025. Visitors were captivated by its sleek design, tactile quality, and an array of innovative features tailored for both live performance and studio production.

Key features of the TempoPAD C16 include:

Wireless Connectivity: BLE Bluetooth MIDI functionality ensures seamless, low-latency performance, offering freedom from cables.

Highly Customizable Controls: Velocity- and pressure-sensitive pads with three modes (Key, Custom, and Dark) allow creators to adapt the device to their unique workflows. The Custom Mode supports personalized note and control assignments, while Key Mode offers octave switching and one-click reset functionality.

Advanced Sequencer: A built-in 16-track, 16-step sequencer with a note repeat feature enables dynamic and creative compositions.

Versatile Compatibility: USB-C connectivity and a 3000mAh rechargeable battery ensure extended use across computers, smartphones, and MIDI devices.

Attendees praised the TempoPAD C16 for its responsiveness, stylish design, and innovative wireless capabilities. Many remarked on the absence of latency during demonstrations and expressed excitement about the product’s potential to streamline creative workflows.

未标题-1(1)

SYNIDO also showcased other innovative products:

TempoPAD P16: A portable controller designed for musicians on the go, the P16 is the best mobile and portable controller available. Its control panel can be accessed directly from your mobile devices, providing convenience on the go. Additionally, With 3.5mm jack output signal with standard MIDI, you can connect any midi-equipped device directly(5 PIN converter included), applying effects/mixing it down along with other tracks.

TempoPAD Z-1: The Z-1 is a controller with 64 backlit drum pads, it is great for musical performances and Music Production, optimizing finger drumming workflow. with its impressive responsiveness, cool lighting effects, and the ability to access 4 octaves at the same time in keys mode.

TempoKEY K25: This MIDI keyboard allows you to program MIDI CC’s directly from the hardware. Every MIDI CC can be changed from the device alone. Every knob can have a different MIDI channel. That plus MIDI out makes it a pretty powerful controller for hardware stuff.

In addition to controllers, SYNIDO’s Live Dock Pro mini audio interface and Live Go streaming sound card also impressed visitors with their portability and versatility. Designed to address a variety of creative scenarios, these devices showcased SYNIDO’s commitment to enhancing the user experience.

画板 7

Inspiring Engagement at the MIDI Association Forum

On January 23, SYNIDO joined industry leaders at the MIDI Association Forum to discuss the latest advancements in MIDI technology and the future of music innovation. In a special session, SYNIDO’s CEO and founder, Marco, shared insights into the brand’s journey and philosophy.

During the forum, Marco highlighted SYNIDO’s bold approach to product design, emphasizing the importance of blending functionality with aesthetics to inspire creativity. “At SYNIDO, we believe that every creator has a story to tell,” Marco said. “Our goal is to provide the tools they need to share their voice effortlessly and authentically.”

Marco also spoke about the skilled team behind SYNIDO, which includes experienced engineers and talented designers. He expressed gratitude for their passion and dedication, stating, “I’m fortunate to work with such an incredible team—it’s their creativity and energy that drive our success every day.”

画板 13

The discussion extended to MIDI’s growing role in the global music industry, with Marco offering his perspective on how Chinese brands like SYNIDO are contributing to innovation and shaping the industry’s future.

Building Connections for a Better Future

Throughout the NAMM Show, SYNIDO engaged in meaningful conversations with content creators, influencers, and music enthusiasts. The team actively collected feedback from visitors, gaining valuable insights to refine and enhance their products. This collaborative spirit reflects SYNIDO’s dedication to putting user needs at the core of its development process.

Attendees were impressed not only by the functionality of SYNIDO’s products but also by their bold designs, which stood out in a sea of traditional offerings. Many expressed excitement for the future of SYNIDO and anticipation for upcoming product releases.

画板 1

A Vision for the Future

The 2025 NAMM Show marked an incredible milestone for SYNIDO, setting the stage for the brand’s continued growth in the global music technology market. As the event ended, SYNIDO extended its heartfelt thanks to all attendees who visited the booth and shared their feedback.

SYNIDO remains committed to innovation, user-centered design, and empowering creators around the world. With plans to unveil more groundbreaking products in the near future, the brand looks forward to future opportunities to connect with music enthusiasts and professionals at events worldwide.

Media Contact
Company Name: SYNIDO
Contact Person: Lucas
Email: Send Email
Country: China
Website: https://www.synido.com/

Biliary Tract Cancer Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharma, Eisai

The Key Biliary Tract Cancer Companies in the market include – Senhwa Biosciences, Incyte, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others.

DelveInsight’s “Biliary Tract Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Biliary Tract Cancer, historical and forecasted epidemiology as well as the Biliary Tract Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Biliary Tract Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Biliary Tract Cancer Market Forecast

Some of the key facts of the Biliary Tract Cancer Market Report:

The Biliary Tract Cancer market size is anticipated to grow with a significant CAGR during the study period (2020–2034)
In December 2024, Jazz Pharmaceuticals announced that the U.S. FDA has granted accelerated approval for Ziihera® (zanidatamab-hrii) 50mg/mL for intravenous administration. This approval is for the treatment of adults with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer (BTC), confirmed by an FDA-approved test.
In November 2024, CTX-009 is a bispecific antibody that targets both Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), two pathways crucial for angiogenesis and tumor vascularization. Preclinical and early clinical data suggest that inhibiting both pathways offers strong anti-tumor effects across various solid tumors, including colorectal, gastric, cholangiocarcinoma, pancreatic, and non-small cell lung cancer. Partial responses have been observed in heavily pre-treated cancer patients who were resistant to approved anti-VEGF therapies. The COMPANION-002 trial, a Phase 2/3 study, is evaluating the combination of CTX-009 and paclitaxel versus paclitaxel alone in patients with previously treated, advanced metastatic or recurrent biliary tract cancers (BTC). Clinical trial information: NCT05506943.
In August 2024, Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on oncology and developing proprietary antibody-based therapeutics for various diseases, today announced the completion of patient enrollment in its COMPANION-002 trial. The trial, a randomized Phase 2/3 study, involves 150 patients and evaluates CTX-009 in individuals with biliary tract cancer (BTC).
In June 2024, Bold Therapeutics, a global leader in the development of innovative metallotherapeutics, announced positive Phase 2 safety and efficacy results for its lead asset, BOLD-100, in the treatment of advanced metastatic biliary tract cancer (BTC) and gastric cancer (GC) at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.
Chemotherapy regimens currently dominate the market. However, several promising therapies in development, such as CX-4945 and CTX-009, are anticipated to significantly impact the Biliary Tract Cancer treatment landscape during the forecast period (2024–2034).
In 2023, the United States held the largest share of the Biliary Tract Cancer market in the 7MM, representing nearly 48% of the market, compared to the EU4, the UK, and Japan.
In 2023, the United States represented approximately 30% of the total incident cases of Biliary Tract Cancer in the 7MM, accounting for the highest number of cases within this region.
In the United States, the majority of Biliary Tract Cancer cases occur in individuals aged 70–79 years, accounting for approximately 30% of all age-specific cases.
In the United States, TP53 mutations were the most prevalent among mutation-specific cases of Biliary Tract Cancer in 2023, followed by KRAS mutations.
Key Biliary Tract Cancer Companies: Senhwa Biosciences, Incyte, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Inc., Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others
Key Biliary Tract Cancer Therapies: PEMAZYRE (pemigatinib), Silmitasertib (CX-4945), Keytruda (pembrolizumab), Imfinzi (durvalumab), Futibatinib (TAS-120), Melphalan, E7090 (tasurgratinib), TT-00420, ARQ 087 (Derazantinib), Lenvima (lenvatinib), Zanidatamab, XmAb20717, Nivolumab + DKN-01, CTX-009, MEDI5752, Brigimadlin, ZB131, GQ1001, BNT141, SO-C101, CT-0508, RAIN-32, AVA6000, DB-1303, and others
The Biliary Tract Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Biliary Tract Cancer pipeline products will significantly revolutionize the Biliary Tract Cancer market dynamics.

Biliary Tract Cancer Overview

Biliary Tract Cancer (BTC) is a rare and aggressive cancer that originates in the bile ducts, which are responsible for carrying bile from the liver to the small intestine. It includes cancers of the bile ducts inside and outside the liver, as well as the gallbladder. Symptoms can be vague and may include jaundice, abdominal pain, and weight loss, often leading to delayed diagnosis. BTC is typically diagnosed in later stages, making treatment more challenging. Treatment options may include surgery, chemotherapy, and targeted therapies, depending on the cancer’s location and stage.

Get a Free sample for the Biliary Tract Cancer Market Report:

https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market

Biliary Tract Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Biliary Tract Cancer Epidemiology Segmentation:

The Biliary Tract Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Biliary Tract Cancer
Prevalent Cases of Biliary Tract Cancer by severity
Gender-specific Prevalence of Biliary Tract Cancer
Diagnosed Cases of Episodic and Chronic Biliary Tract Cancer

Download the report to understand which factors are driving Biliary Tract Cancer epidemiology trends @ Biliary Tract Cancer Epidemiology Forecast

Biliary Tract Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Biliary Tract Cancer market or expected to get launched during the study period. The analysis covers Biliary Tract Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Biliary Tract Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Biliary Tract Cancer Therapies and Key Companies

PEMAZYRE (pemigatinib): Incyte
Silmitasertib (CX-4945): Senhwa Biosciences
Keytruda (pembrolizumab): Merck Sharp & Dohme
Imfinzi (durvalumab): AstraZeneca
Futibatinib (TAS-120): Taiho Oncology
Melphalan: Delcath Systems
E7090 (tasurgratinib): Eisai
TT-00420: TransThera Sciences (Nanjing)
ARQ 087 (Derazantinib): Basilea Pharmaceutica
Lenvima (lenvatinib): Eisai and Merck & Co
Zanidatamab: Zymeworks and BeiGene
XmAb20717: Xencor, Inc.
Nivolumab + DKN-01: Bristol-Myers Squibb/Leap Therapeutics, Inc.
CTX-009: Compass Therapeutics
MEDI5752: AstraZeneca
Brigimadlin: Boehringer Ingelheim
ZB131: ZielBio, Inc.
GQ1001: GeneQuantum Healthcare (Suzhou) Co., Ltd.
BNT141: BioNTech SE
SO-C101: SOTIO Biotech
CT-0508: Carisma Therapeutics Inc
RAIN-32: Rain Oncology Inc
AVA6000: Avacta Life Sciences Ltd
DB-1303: DualityBio Inc.

Discover more about therapies set to grab major Biliary Tract Cancer market share @ Biliary Tract Cancer Treatment Market

Biliary Tract Cancer Market Strengths

The therapeutic landscape in BTCs has expanded considerably in recent years. Combined therapy with chemotherapy, immunotherapy, and modulation of immune checkpoints-mediated signaling pathways are promising strategies.

Biliary Tract Cancer Market Opportunities

Increasing cognizance about different mutations, pathways, and other regimens has changed the focus on curable treatment options with emerging candidates that will lead the growth of the global market.

Scope of the Biliary Tract Cancer Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Biliary Tract Cancer Companies: Senhwa Biosciences, Incyte, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Inc., Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others
Key Biliary Tract Cancer Therapies: PEMAZYRE (pemigatinib), Silmitasertib (CX-4945), Keytruda (pembrolizumab), Imfinzi (durvalumab), Futibatinib (TAS-120), Melphalan, E7090 (tasurgratinib), TT-00420, ARQ 087 (Derazantinib), Lenvima (lenvatinib), Zanidatamab, XmAb20717, Nivolumab + DKN-01, CTX-009, MEDI5752, Brigimadlin, ZB131, GQ1001, BNT141, SO-C101, CT-0508, RAIN-32, AVA6000, DB-1303, and others
Biliary Tract Cancer Therapeutic Assessment: Biliary Tract Cancer current marketed and Biliary Tract Cancer emerging therapies
Biliary Tract Cancer Market Dynamics: Biliary Tract Cancer market drivers and Biliary Tract Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Biliary Tract Cancer Unmet Needs, KOL’s views, Analyst’s views, Biliary Tract Cancer Market Access and Reimbursement

To know more about Biliary Tract Cancer companies working in the treatment market, visit @ Biliary Tract Cancer Clinical Trials and Therapeutic Assessment

Table of Contents

1. Biliary Tract Cancer Market Report Introduction

2. Executive Summary for Biliary Tract Cancer

3. SWOT analysis of Biliary Tract Cancer

4. Biliary Tract Cancer Patient Share (%) Overview at a Glance

5. Biliary Tract Cancer Market Overview at a Glance

6. Biliary Tract Cancer Disease Background and Overview

7. Biliary Tract Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Biliary Tract Cancer

9. Biliary Tract Cancer Current Treatment and Medical Practices

10. Biliary Tract Cancer Unmet Needs

11. Biliary Tract Cancer Emerging Therapies

12. Biliary Tract Cancer Market Outlook

13. Country-Wise Biliary Tract Cancer Market Analysis (2020–2034)

14. Biliary Tract Cancer Market Access and Reimbursement of Therapies

15. Biliary Tract Cancer Market Drivers

16. Biliary Tract Cancer Market Barriers

17. Biliary Tract Cancer Appendix

18. Biliary Tract Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Biliary Tract Cancer Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharma, Eisai

Bone metastasis in Solid Tumor Market Expected to rise, 2034 | Mabwell Bioscience Co., Novartis, Institut Bergonié, Pfizer, GlaxoSmithKline, Amgen, QSAM Therapeutics, Actuate Therapeutics

“Bone metastasis in Solid Tumor Market 2034”

The Bone metastasis in Solid Tumor market growth is driven by factors like increase in the prevalence of Bone metastasis in Solid Tumor, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Bone metastasis in Solid Tumor market report also offers comprehensive insights into the Bone metastasis in Solid Tumor market size, share, Bone metastasis in Solid Tumor epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Bone metastasis in Solid Tumor market size growth forward.

Some of the key highlights from the Bone metastasis in Solid Tumor Market Insights Report:

Several key pharmaceutical companies, including Mabwell (Shanghai) Bioscience Co., Ltd., Novartis, Institut Bergonié, Pfizer, GlaxoSmithKline, Amgen, QSAM Therapeutics Inc., Actuate Therapeutics Inc., Hoffmann-La Roche, and others, are developing novel products to improve the Bone metastasis in Solid Tumor treatment outlook.
In December 2024, Halozyme Therapeutics revealed that the FDA approved Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) from Bristol Myers Squibb. This co-formulation, utilizing Halozyme’s ENHANZE® technology, marks the first subcutaneous PD-1 inhibitor approved for several adult solid tumor indications, both as a standalone treatment and in combination therapies.
Bone metastasis in solid tumors occurs when cancer cells detach from a primary tumor, spread through the bloodstream or lymphatic system, and form secondary tumors in the bones. This condition is more common than primary bone cancers, particularly in adults, and is frequently linked with serious complications. Bone metastasis is the third most common site of metastasis after the lungs and liver, affecting approximately 70% of patients with breast and prostate cancer—the two most prevalent cancers globally. Other cancers, such as kidney, lung, thyroid, bladder, and ovarian, also commonly spread to bones.
Pain is the most prevalent and significant symptom of bone metastasis, but it can also lead to fractures, hypercalcemia, and spinal cord or nerve compression. Bone metastasis disrupts normal bone remodeling, which is regulated by osteoclasts and osteoblasts. Based on its impact on bone remodeling, bone metastasis is classified into osteolytic, osteoblastic, or mixed types.
To assess bone turnover and hypercalcemia, blood tests such as CBC, serum calcium, alkaline phosphatase, and vitamin D levels are performed. Imaging tests like bone scans, PET scans, CT scans, MRIs, and X-rays, as well as biopsies, are essential for diagnosing bone metastasis.
In 2023, the United States had the highest number of bone metastasis cases among the 7MM, with breast cancer accounting for about 41% of these cases. Among the EU4 and the UK, males had a higher incidence of bone metastasis in solid tumors. The most common medications for managing bone issues in these patients include bisphosphonates (pamidronate, zoledronic acid) and denosumab.
The United States dominated the market for bone metastasis in solid tumors in 2023, holding nearly 70% of the market share compared to EU4, the UK, and Japan. Among the EU4 and UK, Germany had the largest market share, while Spain had the smallest.
A few drugs are currently in the clinical development phase for treating bone metastasis from solid tumors like prostate, breast, lung cancers, osteosarcoma, and Ewing’s sarcoma. Cabozantinib, an emerging therapy, shows promise in improving survival for patients with bone metastasis, enhancing both survival and quality of life. Other therapies are also under investigation by companies such as Actuate Therapeutics and QSAM Therapeutics.
Despite advancements in treatment, further understanding of the mechanisms behind bone metastasis across various cancers is needed. Clinical challenges such as improving prediction, early diagnosis, and treatment through biomarkers and therapeutic targets remain. Larger, long-term studies are necessary to confirm the efficacy of current treatments.
As per DelveInsight analysis, the Bone metastasis in Solid Tumor market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Bone metastasis in Solid Tumor Market Landscape

Bone metastasis in Solid Tumor Overview

Bone metastasis in Solid Tumor (GERD) is a chronic condition in which stomach contents, including acid and bile, flow back into the esophagus, causing symptoms like heartburn, regurgitation, and chest pain. It commonly results from a dysfunction of the lower esophageal sphincter (LES), which typically prevents gastric contents from entering the esophagus. Contributing factors include hiatal hernia, poor esophageal motility, obesity, and certain dietary habits, such as consuming spicy or fatty foods, caffeine, and alcohol. GERD can present as non-erosive reflux disease (NERD), where no visible damage occurs to the esophageal lining, or as erosive esophagitis, which involves inflammation and damage to the esophageal tissue.

Symptoms of GERD can vary in intensity and may include heartburn (a burning sensation in the chest, often aggravated by eating or lying down), regurgitation of acid into the mouth, difficulty swallowing (dysphagia), chest pain, and chronic cough. These symptoms can negatively affect quality of life and may lead to complications such as esophageal strictures, Barrett’s esophagus, and esophageal adenocarcinoma if not treated.

Do you know the treatment paradigms for different countries? Download our Bone metastasis in Solid Tumor Market Sample Report

Bone metastasis in Solid Tumor Epidemiology Insights

In 2023, the Bone Metastasis in Solid Tumors market size was approximately USD 1,700 million, and it is projected to grow throughout the study period (2020–2034) across the 7MM.

Bone metastasis in Solid Tumor Epidemiology Segmentation

DelveInsight’s Bone metastasis in Solid Tumor market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Bone metastasis in Solid Tumor historical patient pools and forecasted Bone metastasis in Solid Tumor patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Bone metastasis in Solid Tumor Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

Bone metastasis in Solid Tumor Prevalence
Age-Specific Bone metastasis in Solid Tumor Prevalence
Gender-Specific Bone metastasis in Solid Tumor Prevalence
Diagnosed and Treatable Cases of Bone metastasis in Solid Tumor

Visit for more @ Bone metastasis in Solid Tumor Epidemiological Insights

Bone metastasis in Solid Tumor Market Outlook

Bone is a common site for metastasis in patients with advanced cancer. While bone metastases can occur with any solid tumor, they are most frequently seen in patients with breast, prostate, lung cancer, and renal cell carcinoma. The clinical management of bone metastasis primarily focuses on alleviating pain, preventing bone complications, and maintaining quality of life. Bone-targeting agents (BTA), such as XGEVA (denosumab) and bisphosphonates like zoledronic acid, pamidronate, ibandronate, clodronate, and alendronate, are commonly used treatments to prevent skeletal-related events (SREs) in patients with bone metastasis.

In addition to these treatments, Bayer’s XOFIGO was approved by the US FDA in May 2013 for castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease. While XOFIGO has shown significant efficacy in treating prostate cancer with bone metastases, it is typically introduced after the disease has become symptomatic, limiting its use due to its specific indication and lower real-world treatment preference.

Studies have shown that patient adherence to bone-targeted therapy has been suboptimal, with high rates of treatment discontinuation and switching. These factors have been taken into account when estimating the market size for bone metastasis in solid tumors.

Bone metastasis in Solid Tumor Marketed Drugs

XOFIGO (Radium-223 dichloride): Bayer HealthCare Pharmaceuticals
XGEVA/RANMARK (denosumab): Amgen

Bone metastasis in Solid Tumor Emerging Drugs

Cabozantinib: Exelixis

Bone metastasis in Solid Tumor Key Companies

Mabwell (Shanghai) Bioscience Co., Ltd., Novartis, Institut Bergonié, Pfizer, GlaxoSmithKline, Amgen, QSAM Therapeutics Inc., Actuate Therapeutics Inc., Hoffmann-La Roche, and others

For more information, visit Bone metastasis in Solid Tumor Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Bone metastasis in Solid Tumor Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Bone metastasis in Solid Tumor, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Bone metastasis in Solid Tumor epidemiology in the 7MM
Bone metastasis in Solid Tumor marketed and emerging therapies
Bone metastasis in Solid Tumor companies
Bone metastasis in Solid Tumor market drivers and barriers

Table of Contents:

1 Bone metastasis in Solid Tumor Market Key Comprehensive Insights

2 Bone metastasis in Solid Tumor Market Report Introduction

3 Competitive Intelligence Analysis for Bone metastasis in Solid Tumor

4 Bone metastasis in Solid Tumor Market Analysis Overview at a Glance

5 Executive Summary of Bone metastasis in Solid Tumor

6 Bone metastasis in Solid Tumor Epidemiology and Market Methodology

7 Bone metastasis in Solid Tumor Epidemiology and Patient Population

8 Bone metastasis in Solid Tumor Patient Journey

9 Bone metastasis in Solid Tumor Treatment Algorithm, Bone metastasis in Solid Tumor Current Treatment, and Medical Practices

10 Key Endpoints in Bone metastasis in Solid Tumor Clinical Trials

11 Bone metastasis in Solid Tumor Marketed Therapies

12 Bone metastasis in Solid Tumor Emerging Therapies

13 Bone metastasis in Solid Tumor: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Bone metastasis in Solid Tumor

16 Bone metastasis in Solid Tumor Market Key Opinion Leaders Reviews

18 Bone metastasis in Solid Tumor Market Drivers

19 Bone metastasis in Solid Tumor Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Bone metastasis in Solid Tumor Epidemiology 2034

DelveInsight’s “Bone metastasis in Solid Tumor – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Bone metastasis in Solid Tumor epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Bone metastasis in Solid Tumor Pipeline 2024

“Bone metastasis in Solid Tumor Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Bone metastasis in Solid Tumor market. A detailed picture of the Bone metastasis in Solid Tumor pipeline landscape is provided, which includes the disease overview and Bone metastasis in Solid Tumor treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bone metastasis in Solid Tumor Market Expected to rise, 2034 | Mabwell Bioscience Co., Novartis, Institut Bergonié, Pfizer, GlaxoSmithKline, Amgen, QSAM Therapeutics, Actuate Therapeutics

O’Connor Company Reports $55.7M Revenue in 2024, Sets Ambitious Growth Goals for 2025

O’Connor Company expands its footprint with key projects across multiple states and aims for significant topline growth.

Pinehurst – Jan 29, 2025 – O’Connor Company, a leading name in commercial construction specializing in delivering high-quality projects across diverse sectors, is proud to announce its continued growth and success in 2024, reporting a top-line revenue of $55.7 million, representing a 49% year-over-year increase from 2023. With a strong backlog of $120 million and disciplined project execution, O’Connor Company is poised for further expansion in 2025.

The company has secured several major projects across the East Coast, underscoring its growing presence in the commercial construction industry. Key projects in 2024 include:

Champlain, NY: $4.5 million
Newburgh, NY: $12.2 million
Charlotte, NC: $12.0 million
Bethel, NY: $5.8 million
Lillington, NC: $4.5 million
Cary, NC: $9.8 million
Fayetteville, NC: $10.4 million

“Our success in 2024 is a testament to our team’s unwavering dedication and strategic approach to growth,” said Clark Lowe, President and CEO of O’Connor Company. “We are committed to continuing our momentum into 2025 by expanding our market reach, enhancing operational efficiency, and investing in our people.”

Looking ahead, O’Connor Company has set an ambitious target of $85 million in topline revenue for 2025, reflecting a projected 55% growth. To support this expansion, the company plans to onboard 10 additional full-time employees in Q1 and further grow its remote-based workforce throughout the year.

“As we move forward, our focus remains on maintaining a robust project pipeline and delivering exceptional results for our clients,” added Lowe. “Our disciplined execution and commitment to innovation position us for success in the years to come.”

For more information about O’Connor Company and its ongoing projects, please visit https://www.buildoconnor.com/

About O’Connor Company:

O’Connor Company is a leading name in commercial construction, specializing in delivering high-quality projects across diverse sectors. With a reputation for innovation, efficiency, and client satisfaction, O’Connor Company leverages cutting-edge practices to redefine the construction industry. From healthcare to retail and now community-focused initiatives, the company remains at the forefront of delivering projects that make a lasting impact.

Media Contact
Company Name: Otter PR
Contact Person: Mark Hashem
Email: Send Email
Phone: 7274339069
Address:100 E Pine St Suite 110
City: Orlando
State: Florida
Country: United States
Website: OtterPR.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: O’Connor Company Reports $55.7M Revenue in 2024, Sets Ambitious Growth Goals for 2025

Golden Years Home Care Supports Family Caregivers with Respite Care in Sacramento County

Providing peace of mind to families through compassionate in-home care Sacramento County

Sacramento County, CA – Golden Years Home Care proudly announces its commitment to supporting family caregivers with high-quality respite care in Sacramento County. This initiative ensures seniors receive the attentive and compassionate care they deserve while allowing caregivers to rest, recharge, and maintain balance.

“At Golden Years Home Care, we understand the challenges caregivers face and the importance of providing a trusted solution,” said Ken Ballard, founder of Golden Years Home Care. “Our respite care services are thoughtfully designed to enhance the well-being of families and ensure seniors receive the highest quality in-home care in Sacramento County. We are dedicated to being a dependable partner in the caregiving journey, helping families thrive together.”

Respite care plays a vital role in maintaining the health and well-being of family caregivers. Often, caregivers face significant physical, emotional, and mental demands while supporting their loved ones, which can lead to burnout if left unaddressed. By offering short-term professional care, Golden Years Home Care provides a much-needed opportunity for caregivers to take a break, rejuvenate, and return to their responsibilities with renewed energy and focus.

One of the primary benefits of respite care is its ability to improve overall family dynamics. Caregiving is often a team effort that can strain relationships when one person takes on most responsibilities. Respite care allows families to share the load and ensures seniors receive consistent, high-quality attention, reducing stress and promoting a harmonious home environment.

For seniors, respite care offers more than just temporary support. It introduces them to new caregivers who bring fresh perspectives, compassionate care, and a professional approach to their unique needs. This experience can enhance seniors’ emotional well-being, foster social engagement, and ensure they feel valued and cared for in a personalized setting.

Golden Years Home Care offers a range of services tailored to meet the unique needs of each senior and their family. From daily living assistance to specialized care for those with chronic conditions or cognitive impairments, their approach emphasizes safety, dignity, and comfort. With growing demand for reliable in-home care solutions, their respite care services are a much-needed lifeline for families navigating the complexities of elder care.

Families in Sacramento County looking for compassionate and professional respite care for their loved ones can turn to Golden Years Home Care for dependable support. For more information about Golden Years Home Care and their respite care in Sacramento County, please visit their website at https://goldenyearshomecare.com/sacramento-ca.

About Golden Years Home Care:

Golden Years Home Care is a leading provider of personalized in-home care services in Sacramento County, CA. Dedicated to empowering families and improving the lives of seniors, Golden Years Home Care delivers tailored care plans that prioritize dignity, safety, and independence. With a team of skilled and compassionate caregivers, they remain committed to excellence in elder care.

Media Contact
Company Name: Golden Years Home Care (Sacramento, CA)
Email: Send Email
Phone: (916) 333-0383
Address:717 K St #211
City: Sacramento
State: California 95814
Country: United States
Website: https://goldenyearshomecare.com/sacramento-ca/

Alliance Senior Care Elevates Personal Home Care in Bloomfield Hills, MI, with an Unwavering Commitment to Quality

Providing families in Bloomfield Hills with compassionate, personalized in-home care services to ensure their loved ones receive the highest support standard.

Bloomfield Hills, MI – Alliance Senior Care is proud to announce its continued dedication to providing exceptional personal home care in Bloomfield Hills, MI. With a steadfast commitment to ensuring that families have access to compassionate and reliable in-home care services, Alliance Senior Care aims to give peace of mind to those seeking at-home personal care for their elderly loved ones.

“At Alliance Senior Care, we understand how crucial it is to ensure that every individual receives personalized and high-quality care,” said Dina Hurnevich, owner of Alliance Senior Care. “Our mission is to provide families with trusted, compassionate support that allows their loved ones to age comfortably and safely at home. We take great pride in helping families know that their loved ones are in the best hands, receiving the care they need to thrive.”

The need for reliable, high-quality in-home care is more critical than ever, particularly for families with elderly members who require personalized attention. By offering comprehensive and adaptable in-home personal care services in Bloomfield Hills, Alliance Senior Care helps seniors maintain their independence and quality of life while remaining in a familiar environment. Services include assistance with daily activities, chronic condition management, and specialized care tailored to each client’s needs.

Personal home care provides seniors with the essential support they need to maintain their independence while living in the comfort and familiarity of their own homes. This type of care allows seniors to stay connected to their communities, continue daily routines, and enjoy meaningful interactions with friends and family. Unlike institutional settings, personal home care offers flexibility and one-on-one attention, ensuring that every aspect of care is tailored to the individual’s preferences and health needs.

The importance of personal home care goes beyond physical well-being. It also supports seniors’ emotional and psychological health by reducing feelings of loneliness and isolation. Personalized care services create a sense of companionship and security, vital for mental health. For seniors dealing with chronic conditions or cognitive decline, consistent and compassionate care helps mitigate anxiety and fosters a positive outlook on life.

Additionally, personal home care provides peace of mind to family members who may be unable to provide full-time care due to work and personal obligations. Knowing that their loved ones are receiving professional, high-quality care allows families to focus on their responsibilities while remaining confident that their elderly relatives are in capable and caring hands.

Families in Bloomfield Hills, MI, seeking personal home care services can trust Alliance Senior Care to provide the support their loved ones deserve. The personalized approach ensures that each care plan is specifically designed to meet the unique requirements of every senior, promoting well-being, safety, and dignity.

For more information about Alliance Senior Care and their personal home care in Bloomfield Hills, MI, please visit their website at https://alliancesrcare.com.

About Alliance Senior Care:

Alliance Senior Care is a leading provider of in-home senior care services in Bloomfield Hills, MI. Focusing on personalized, compassionate care, its team of dedicated professionals ensures that seniors receive the support they need to live safely and comfortably at home. Committed to excellence, Alliance Senior Care continues to be a trusted resource for families seeking quality personal care for their loved ones.

Media Contact
Company Name: Alliance Senior Care
Contact Person: Dina Hurnevich
Email: Send Email
Phone: +1 248 274 2170
Address:7 W SQUARE LAKE RD
City: Bloomfield Hills
State: MI 48302-0462
Country: United States
Website: alliancesrcare.com

Acne Vulgaris Market Expected to rise, 2034 | Pelthos Therapeutics, Dermata Therapeutics, Botanix Pharmaceuticals, AOBiome LLC, BioPharmX, Timber Pharmaceuticals, expected to drive market

“Acne Vulgaris Market 2034”

The Acne Vulgaris market growth is driven by factors like increase in the prevalence of Acne Vulgaris, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Acne Vulgaris market report also offers comprehensive insights into the Acne Vulgaris market size, share, Acne Vulgaris epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Acne Vulgaris market size growth forward.

Some of the key highlights from the Acne Vulgaris Market Insights Report:

Several key pharmaceutical companies, including ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno.N Corporation, Jeil Pharmaceutical, Onconic Therapeutics, Plexxikon, Renexxion, Taiho Pharmaceutical, Takeda, Trio Medicines, and others, are developing novel products to improve the Acne Vulgaris treatment outlook.
In December 2024, Dermata Therapeutics, Inc. obtained FDA approval for the brand name Xyngari (formerly known as DMT310) for its Phase III acne drug candidate. Approval is contingent upon the successful submission and acceptance of a New Drug Application (NDA).
In October 2024, Accure Acne, Inc.™ received FDA clearance (K242035) for the treatment of mild to severe inflammatory acne vulgaris.
In 2023, the US had the largest share of the Acne Vulgaris market among the 7MM, reaching approximately USD 2,949 million, with expectations for further growth by 2034. Across the 7MM, there were around 29,433 thousand diagnosed prevalent cases of acne vulgaris in 2023, a figure that is anticipated to rise during the forecast period (2024-2034). Contributing factors to this increase include hormonal fluctuations, dietary factors, genetic predispositions, and environmental influences like pollution.
The prevalence of acne vulgaris is categorized by age groups: 15-19 years, 20-29 years, 30-39 years, 40-49 years, and 50 years and older. In the United States, the 15-19 age group had the highest number of cases, with approximately 5,853 thousand cases in 2023.
The emerging drug SB204 is expected to launch in the US market by 2027 and could potentially alleviate the disease burden of acne vulgaris in the coming years.
In 2023, there were approximately 140,217 thousand prevalent cases of Acne Vulgaris across the 7MM, with around 69,500 thousand cases in the US. These figures are expected to rise consistently over the forecast period.
As per DelveInsight analysis, the Acne Vulgaris market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Acne Vulgaris Market Landscape

Acne Vulgaris Overview

Acne vulgaris is a chronic inflammatory skin condition primarily affecting the pilosebaceous units, with adolescents being the most commonly impacted group. It presents with pimples, blackheads, and whiteheads, and its severity ranges from mild to severe, depending on the presence of non-inflammatory and inflammatory lesions, erythema, and scarring. The condition results from a combination of hormonal changes, excessive sebum production, follicular hyperkeratinization, bacterial growth, and inflammation, influenced by genetics, medications, and environmental factors. Common symptoms include comedones, inflammatory lesions, and scarring.

The growing demand for advanced skincare solutions and non-invasive treatments is driving the acne treatment market. Diagnosis typically involves a clinical examination of the skin, and additional tests such as biopsies, microbial cultures, hormonal evaluations, and liver function tests may be performed to rule out other conditions and better understand the disease.

Do you know the treatment paradigms for different countries? Download our Acne Vulgaris Market Sample Report

Acne Vulgaris Epidemiology Segmentation

DelveInsight’s Acne Vulgaris market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Acne Vulgaris historical patient pools and forecasted Acne Vulgaris patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Acne Vulgaris Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

Acne Vulgaris Prevalence
Age-Specific Acne Vulgaris Prevalence
Gender-Specific Acne Vulgaris Prevalence
Diagnosed and Treatable Cases of Acne Vulgaris

Visit for more @ Acne Vulgaris Epidemiological Insights

Acne Vulgaris Market Outlook

Effective acne management requires a holistic approach that addresses underlying causes, incorporates lifestyle changes, and includes topical and systemic treatments when necessary. The growing prevalence of acne, increased skincare awareness, and the demand for alternative treatments are driving the current Acne Vulgaris treatment market.

Recent advancements include various topical and systemic therapies targeting different aspects of acne’s complex pathogenesis. Topical treatments like salicylic acid and azelaic acid help improve skin moisture, reduce inflammation, and clear comedones. Severe cases are treated with systemic options such as oral antibiotics (tetracycline, doxycycline), oral retinoids (isotretinoin), and hormonal agents like spironolactone.

Despite existing strategies, current treatments do not fully address the disease burden, highlighting the urgent need for new therapies. The market is eagerly awaiting the launch of promising treatments, including SB204 (Pelthos Therapeutics), DMT310 (Dermata Therapeutics), B244 (AOBiome LLC.), BPX-01 (Timber Pharmaceuticals), and BTX-1503 (Botanix Pharmaceuticals), which could address a critical global public health need if proven effective.

Acne Vulgaris Marketed Drugs

AKLIEF (Trifarotene)/ CD-5789: Galderma S.A.
AMZEEQ (minocycline): Journey Medical Corporation/Vyne Therapeutics Inc.
ARAZLO (tazarotene): Bausch Health Companies Inc. / Ortho Dermatologics

Acne Vulgaris Emerging Drugs

SB204: Pelthos Therapeutics
B244: AOBiome LLC
DMT310: Dermata Therapeutics

Acne Vulgaris Key Companies

Pelthos Therapeutics, Dermata Therapeutics, Botanix Pharmaceuticals, AOBiome LLC, BioPharmX, Timber Pharmaceuticals, and others

For more information, visit Acne Vulgaris Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Acne Vulgaris Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Acne Vulgaris, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Acne Vulgaris epidemiology in the 7MM
Acne Vulgaris marketed and emerging therapies
Acne Vulgaris companies
Acne Vulgaris market drivers and barriers

Table of Contents:

1 Acne Vulgaris Market Key Comprehensive Insights

2 Acne Vulgaris Market Report Introduction

3 Competitive Intelligence Analysis for Acne Vulgaris

4 Acne Vulgaris Market Analysis Overview at a Glance

5 Executive Summary of Acne Vulgaris

6 Acne Vulgaris Epidemiology and Market Methodology

7 Acne Vulgaris Epidemiology and Patient Population

8 Acne Vulgaris Patient Journey

9 Acne Vulgaris Treatment Algorithm, Acne Vulgaris Current Treatment, and Medical Practices

10 Key Endpoints in Acne Vulgaris Clinical Trials

11 Acne Vulgaris Marketed Therapies

12 Acne Vulgaris Emerging Therapies

13 Acne Vulgaris: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Acne Vulgaris

16 Acne Vulgaris Market Key Opinion Leaders Reviews

18 Acne Vulgaris Market Drivers

19 Acne Vulgaris Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Acne Vulgaris Epidemiology 2034

DelveInsight’s “Acne Vulgaris – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Acne Vulgaris epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Acne Vulgaris Pipeline 2024

“Acne Vulgaris Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Acne Vulgaris market. A detailed picture of the Acne Vulgaris pipeline landscape is provided, which includes the disease overview and Acne Vulgaris treatment guidelines.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acne Vulgaris Market Expected to rise, 2034 | Pelthos Therapeutics, Dermata Therapeutics, Botanix Pharmaceuticals, AOBiome LLC, BioPharmX, Timber Pharmaceuticals, expected to drive market

ZenaTech Inc. (Nasdaq: ZENA): Harnessing AI, Drones, and Quantum Computing to Revolutionize Industries

Artificial intelligence is no longer a buzzword—it’s reshaping industries and redefining competitive advantages. As global AI spending is projected to soar to $337 billion by 2025 (IDC), much of this investment is flowing into companies embedding AI into real-world operations. From streamlining agriculture to managing natural disasters, AI is powering transformative solutions in unexpected areas.

While industry giants dominate headlines, innovative up-and-comers like ZenaTech Inc. (Nasdaq: ZENA) are tackling critical challenges with practical AI applications. Unlike the tech behemoths, ZenaTech focuses on integrating AI into essential industries—agriculture, wildfire management, and defense—where efficient solutions can have immediate and meaningful impact.

This approach, coupled with ZenaTech’s commitment to cutting-edge technologies like Quantum Computing and its accessible Drone-as-a-Service (DaaS) model, positions the company as a rising star in the AI-driven transformation of traditional sectors.

ZenaTech: Driving Innovation with AI, Quantum Computing, and Drones

ZENA continues to push the boundaries of technological innovation through its focus on AI-driven drones, Quantum Computing, and its scalable Drone-as-a-Service (DaaS) business model. The company is making headlines with its acquisitions, geographical expansion, and groundbreaking solutions aimed at addressing real-world challenges in industries like agriculture, disaster management, and land surveying.

Expanding Through Acquisitions in the Southeast

ZENA recently announced its fourth Letter of Intent (LOI) to acquire a land survey engineering firm in Florida, solidifying its presence in the Southeast U.S. region. This acquisition supports ZenaTech’s vision of creating a national DaaS network, offering AI-powered drone solutions to industries and government agencies. The ZenaDrone 1000, a multifunction AI-powered drone, will play a central role in helping Florida manage natural disasters, particularly hurricanes. With an average cost of $22.8 billion in damages per hurricane, according to the Office for Coastal Management, the deployment of drone swarms for real-time data collection, search and rescue, and resource allocation has the potential to significantly improve response efficiency and reduce costs.

This acquisition follows two others completed earlier this month, forming the foundation of ZenaTech’s national DaaS rollout. The company’s roll-up strategy targets established land survey engineering firms with experienced teams and a proven customer base, leveraging their expertise to enhance drone-based surveying operations.

Drone Swarms: Revolutionizing Disaster Management

A key component of ZenaTech’s innovation is its AI-powered drone swarms. These drones work collaboratively using advanced algorithms to share data, coordinate flight paths, and adapt dynamically to changing conditions. In hurricane-prone areas like Florida, they can assist with disaster preparation and recovery by mapping high-risk areas, monitoring real-time weather and environmental data, conducting search-and-rescue operations using GPS and thermal imaging, and delivering supplies to inaccessible regions.

These advancements are part of ZenaTech’s larger Sky Traffic project, which combines drone swarm technology with Quantum Computing algorithms to process vast amounts of real-time data. By hiring experts in physics and Quantum Computing, the company aims to optimize disaster response and other high-value applications.

Quantum Computing: Amplifying AI’s Impact

ZenaTech’s integration of Quantum Computing into its AI solutions sets it apart from competitors. Quantum technology enhances data processing speeds and precision, enabling groundbreaking applications in fields such as wildfire prevention and enterprise operations. For example, predictive analytics powered by Quantum Computing allow ZenaTech’s drones to forecast wildfire outbreaks with remarkable accuracy by analyzing weather, vegetation, and terrain data. Additionally, Quantum-enhanced AI is being developed to streamline workforce scheduling, logistics, and operational planning, diversifying ZenaTech’s revenue streams and targeting the $4 billion Quantum Computing market.

Drone-as-a-Service: A Scalable Business Model

ZenaTech’s DaaS model offers a cost-effective, pay-as-you-go solution for businesses and government agencies, eliminating the need for high upfront investments in drone hardware and software. Industries like construction, agriculture, and oil and gas benefit from ZenaTech’s advanced drone capabilities for applications such as land surveying, crop management, compliance, and safety inspections.

This approach mirrors the success of platforms like Amazon Web Services, with ZenaTech owning the drones and employing trained pilots, allowing customers to focus on leveraging the technology’s benefits without operational burdens. The U.S. Surveying and Mapping Services industry, valued at $10.3 billion and growing at 3% annually, represents a significant market opportunity for ZenaTech’s drone-driven disruption.

International Growth and Market Expansion

In addition to its U.S. operations, ZenaTech’s listing on the Mexican Stock Exchange (BMV) under the symbol “ZENA” marks a milestone in its international expansion. This move provides greater liquidity for shareholders and broadens the company’s exposure to international investors. “This additional listing not only enhances our global reach but also aligns with our goal of delivering shareholder value as we expand into new geographical markets,” said CEO Shaun Passley, Ph.D.

Why ZenaTech

ZenaTech Inc.’s (Nasdaq: ZENA) unique combination of AI, Quantum Computing, and practical applications positions it at the forefront of multiple high-growth industries. The company is addressing markets with substantial growth potential, including the $10.3 billion land surveying industry and the $1.5 trillion AI market by 2030. By integrating Quantum Computing with AI, ZenaTech delivers advanced solutions that tackle complex challenges in disaster management, agriculture, and beyond. Its DaaS model could ensure a consistent cash flow, while its expertise in navigating FAA certification and regulatory landscapes demonstrates readiness for scalable growth.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ZenaTech Ltd. to assist in the production and distribution of content related to ZENA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ZenaTech Inc. (Nasdaq: ZENA): Harnessing AI, Drones, and Quantum Computing to Revolutionize Industries

Understanding Water Damage Repair and Restoration: A Guide to Protecting Home

“Workman Restoration”

Water damage is one of the most common and devastating issues homeowners face. Whether it’s from a burst pipe, a leaking roof, or a natural disaster, water can wreak havoc on a home if not addressed promptly and effectively. This is where professional water damage repair and water damage restoration services come into play. Companies like Workman Restoration specialize in helping homeowners recover from water-related disasters, ensuring their properties are safe, dry, and restored to their original condition.

When water damage occurs, the first step is water damage repair. This involves identifying the source of the water, stopping it, and removing any standing water. Repairing water damage isn’t just about drying things out; it’s about preventing further issues like mold growth, structural damage, and electrical hazards. Workman Restoration uses advanced equipment, such as industrial-grade pumps and dehumidifiers, to extract water quickly and efficiently. This step is critical because the longer water sits, the more damage it can cause.

Once the water is removed, the next phase is water damage restoration. Restoration goes beyond repair—it focuses on bringing the property back to its pre-damage state. This includes drying out affected areas, sanitizing surfaces to prevent mold and bacteria, and repairing or replacing damaged materials like drywall, flooring, and insulation. Workman Restoration’s team of experts is trained to handle every aspect of the restoration process, ensuring that no detail is overlooked.

For homeowners, residential water damage restoration is particularly important because it directly impacts their living environment. A home is more than just a building; it’s a space where families live, grow, and create memories. When water damage strikes, it can disrupt daily life and create unsafe conditions. Professional water damage restoration services ensure that homes are not only restored but also safe for occupants. Workman Restoration understands the emotional toll water damage can take, which is why they prioritize quick response times and compassionate service.

One of the key benefits of hiring professionals for water damage repair and restoration is their ability to handle complex situations. For example, water damage often hides in hard-to-reach places like behind walls or under flooring. Without the right tools and expertise, these hidden issues can go unnoticed, leading to long-term problems like mold growth or weakened structures. Workman Restoration uses thermal imaging and moisture detection technology to identify hidden water damage, ensuring that every affected area is addressed.

Another critical aspect of water damage restoration services is mold prevention. Mold can begin to grow within 24-48 hours of water exposure, posing serious health risks and further damaging the property. Workman Restoration takes proactive measures to prevent mold by thoroughly drying and sanitizing affected areas. They also provide recommendations for maintaining a dry and healthy home environment, such as improving ventilation or installing sump pumps in flood-prone areas.

For residential water damage restoration, timing is everything. The sooner water damage is addressed, the less severe the consequences will be. Workman Restoration offers 24/7 emergency services, ensuring that homeowners can get help whenever they need it. Their rapid response not only minimizes damage but also reduces the overall cost of repairs. Delaying water damage repair can lead to more extensive damage, higher repair costs, and even health hazards, making it essential to act quickly.

In addition to emergency services, Workman Restoration provides comprehensive water damage restoration services that cover every step of the process. From initial assessment and water extraction to final repairs and restoration, their team works diligently to restore homes to their original condition. They also work closely with insurance companies to simplify the claims process, making it easier for homeowners to focus on recovery rather than paperwork.

Water damage can be overwhelming, but understanding the importance of professional water damage repair and restoration can make all the difference. By addressing the issue promptly and effectively, homeowners can protect their property, their health, and their peace of mind. Workman Restoration’s expertise in residential water damage restoration ensures that every home is treated with care and precision, giving homeowners the confidence that their property is in good hands.

The key takeaway is that water damage doesn’t have to be a disaster. With the right knowledge and professional help, it’s possible to restore a home to its former glory. Whether it’s a minor leak or a major flood, water damage restoration services like those offered by Workman Restoration provide the expertise and tools needed to handle any situation. By acting quickly and relying on professionals, homeowners can minimize damage, prevent future issues, and ensure their homes remain safe and comfortable for years to come.

Media Contact
Company Name: Workman Restoration
Contact Person: Support
Email: Send Email
Phone: (689) 265-5131
Address:206 S Orange Ave
City: Orlando
State: FL 32801
Country: United States
Website: https://workmanrestorationorlando.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Understanding Water Damage Repair and Restoration: A Guide to Protecting Home